Mide Karsinomunda Prediktif Faktörler

Amaç: Serum albumin, albumin-globulin oranı AGR , nötrofil/lenfosit N/L değerlerinin mide kanseri hastalarında sağkalım üzerine etkileri araştırıldı.Gereç ve Yöntem: Ön çalışma niteliğindeki bu çalışmaya kemoterapi değerlendirmesindeki 46 hastanın biyokimyasal parametreleri retrospektif olarak arşiv kayıtlarından alındı. AGR=Albumin/Total Protein-Albumin formülüyle AGR değerleri hesaplandı. Büyükten küçüğe doğru sıralanıp, Receiver Operating Characteristic ROC analiziyle AGR düşük-yüksek olarak değerlendirildi. Albumin ve N/L oranları da benzer şekilde gruplandırıldı.Bulgular: AGR’ nin ROC analiziyle tespit edilen cut-off değeri; 1.295 % 62.5 duyarlılık, % 50 özgüllük idi. Kaplan-Meier metoduyla yüksek AGR grubunda düşük AGR grubuna göre daha uzun ortalama genel sağkalım OS tespit edildi. Sırasıyla 27 ± 21 aya karşı 26 ± 26 ay , p: 0.706, % 95 CI: 0.295-0.791 . ROC analiziyle albumin için cut-off değeri; 4.05 mg/dl % 50 duyarlılık, % 58.5 özgüllük idi. Kaplan-Meier metoduyla düşük albumin seviyeli olan grupda yüksek albumin seviyeli olan grupa göre daha uzun OS tespit edildi. OS; 30 ± 26 aya karşı 22 ± 21 ay , p: 0.524, % 95 CI:0.195-0.660 dı, sırasıyla. ROC analizine göre N/L’ nin cut-off değeri: 2.445 % 50 duyarlılık, % 60.5 özgüllük idi. Kaplan-Meier metoduyla OS’ si yüksek olan N/L grubunda düşük olan gruba göre daha uzun olarak tespit edildi 32 ± 29 aya karşı 23 ± 19 ay , p:0.965, % 95 CI: 0.247-0.748 idi. Logistic regression analizi ile AGR, N/L, albumin düzeyleri ile mortalite ve OS arasında istatitiki anlamlı ilişki tespit edilmemiştir.Sonuç: AGR, N/L, albumin düzeyleri mide kanserli hastalardaki mortaliteyi, sağkalımı öngörmede tek başlarına yeterli parametreler olmayabilirler. Vaka sayılarının arttırılmasıyla daha net sonuçlar elde edilebilinir

Introduction: Serum albumin, albumin-globulin ratio AGR , neutrophil/lymphocyte N / L levels in patients with gastric carcinoma were investigated on survival impact. Methods: This study was planned as a pilot study. Biochemical parameters of 46 patients were obtained from archive retrospectively. AGR levels were calculated by AGR =albumin/Total Protein- Albumin formula. They were sorted by descending, AGR was evaualted with lower and upper by using ROC. Albumin and N/L were divided similarly.Results: AGR cut-off value was 1.295 with ROC, in ROC: 0.543 62.5% sensitivity, 50% specificity . The mean overall survival’s OS detected 20 months in lower AGR group, 28 ± 21 months in upper AGR group. A longer OS was detected in upper AGR group by Kaplan-Meier p = 0.706, 95% CI: 0.295-0.791 . According to ROC of level albumin’s cut-off value was 4.05 mg/dL in the ROC: 0.545, 50% sensitivity, 58.5% specificity . The OS was detected 22 ± 21 months, in lower albumin group, 30 ± 26 months in upper albumin group. A longer OS was detected in upper albumin group by Kaplan-Meier p=0.524, 95% CI:0.195-0.660 . According to ROC, cut-off value of N/L was 2.445 in ROC:0.495, 50% sensitivity, 60.5% specificity . The OS was detected 32 ± 29 months in upper N/L group, 23 ±19 months in lower N/L group. A longer OS was determined in upper N/L group by Kaplan-Meier p=0.965, 95% CI:0.247-0.748 . There were no statistical significant differences regarding prediction of survival, mortality for patient’s AGR, N/L, albumin levels by logistic regression analysis.Discussion: AGR, N/L, albumin levels may be not alone sufficient for prediction of survival, and mortality parameters in gastric cancer. It can be obtained more accurate results by increasing the number of cases

___

  • Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Canc Clin 2011; 61: 69-90.
  • World Health Organization.International Agency for rese- arch on cancer. Globocan Turkey. 2012.
  • World Health Organization. Cancer. Accesed 11 Aug 2013. Available from: URL: http://www.who.int/mediacentre/fa- ctsheets/fs297/en/
  • Chen K, Xu XW, Mou YP, et al. Systematic review and me- ta-analysis of laparoscopic and open gastrectomy for ad- vanced gastric cancer. World J Surg Oncol 2013; 11: 182.
  • Wang W, Li Z, Tang J, et al. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a me- ta-analysis. J Cancer Res Clin Oncol 2013; 139: 1721-34.
  • Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013; 30: 119-29.
  • Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. GE Adenocarcinoma Metaanalysis Group. Perioperative che- mo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal jun- ction, and lower esophagus. Cochrane Database Syst Rev 2013; 5.
  • Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systemic review and meta-analy- sis based on aggregate. J Clin Oncol 2006; 24: 2903-9.
  • Gospodarowicz M, Mackillop W, O’Sullivian B. Prognostic factors in clinical decision making: the future. Cancer 2001; 98: 1866-95.
  • Amini N, Spolverato G, Kim Y, et al. Clinicopathological features and prognosis of gastric cardia adenocarcinoma: A multi-institutional U.S. study. J Surg Oncol 2015; 3:285-92.
  • Gaspar MJ, Arribas I, Coca MC et al. Prognostic value of carcinoembryonic antigen, CA19-9, and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318-22.
  • Wobbes T, Thomas CMG, Segers MFG, et al. Evaluation of seven tumors markers in the pretreatments of patients gast- ric carcinoma. Cancer 1992; 69: 2036-41.
  • McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-6.
  • Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroente- rology 2001; 48:1199-201.
  • Goldwasser P, Felman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50: 693-703.
  • OkamuraT, Hayakawa T, Kadowaki T, et al. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004; 57: 1188-95.
  • Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system risk prediction of hospital mortalityfor critically ill hospitalized adults. Chest 1991; 100: 1619-36.
  • Oñate-Ocaña LF Aiello-Crocifoglio V, Gallardo-Rincón D., et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007; 14: 381-9.
  • Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-25.
  • Azab B, Kedia S, Shah N, et al. The value of the pretreatment albumin/globulin ratio in predicting the long term survival in colorectal cancer. Int J Colorectal Dis 2013; 28:1629-36.
  • Azab BN, Bhatt VR, Vonfrolio S, et al. Value of the pretre- atment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 2013; 206: 764-70.
  • Shen JJ, Niu WN, Zhou M, et al. Association of Epstein Barr Virus A73 Gene Polymorphism with Nasopharyngeal Car- cinoma. Genet Test Mol Biomarkers 2014; 1:2
  • Friedman JM, Stavas MJ, C melak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol 2014; 4:781-91.
  • Mazarico E, Gómez-Roig MD, Miñano J, et al. Relationship of human papilloma virus multiple genotype infection with patient’s age and type of cervical lesion. Eur J Gynaecol On- col 2014; 35:378-81.
  • Coussesns LM, Werb Z. Inflamation and cancer. Nature 2002; 420: 860-7.
  • Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univa- riate and multivariate analyses including recursive partiti- oning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-30.
  • Kobayashi N, Usui S, Kikuchi S, et al. Preoperative lymp- hocyte count is an independent prognostic factor in no- de-negative non-small cell lung cancer. Lung Cancer 2012; 75:223-7.
  • Wang S, Zhang Z, Fang F, et al. The neutrophil/lymphocy- te ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2011; 2: 735-40.
  • Kao SC, Pavlakis N, Harvie R, et al. High blood neutrop- hil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805-13.
  • Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-ly- mphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy Ann Surg Oncol 2009; 16: 614-22.
  • Kunisaki C, Takahashi M, Ono HA, Oshima T. Inflammati- on-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology 2012; 83:183-91.